According to the WHO, the incidence of cancer is expected to rise by about 70% over the next 20 years. Half of those diagnosed with cancer will survive for at least a decade, and this survival rate is expected to increase significantly in the future.
We count on a multidisciplinary consortium, where different stakeholders of this process are part of the study, from scientists to industry, and from healthcare providers (physicians and nurses) to patients.
Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.
This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118
RESILIENCE is a CNIC project with a multidisciplinary consortium | All Rights Reserved 2022
We use our own and third-party cookies that allow the operation and provision of the services offered on the Website, as well as the development of statistical information through the analysis of your browsing habits . By clicking “Accept All” you expressly consent to the use of all cookies. If you wish to reject them or cutomise your settings, click on Cookies management . For more information please read our Cookies Policy .
Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.
In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions